Eric Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on X:
“Phase 3 HERTHENA-Lung02 study:
-
HER3-DXd v chemo in EGFRm NSCLC post 3G TKI
-
mPFS: 5.8 v 5.4 mo (HR 0.77)
-
ORR: 35% v 25%
-
PFS: 5.4 v 4.2 mo (HR 0.75)
-
TEAEs G≥3: 73% v 57%, mostly thrombocytopenia
-
5% ILD (with 2 G5 events).”
More posts featuring Eric Singhi.